XML 42 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
License and Collaboration Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 13, 2018
Aug. 23, 2017
Apr. 30, 2018
Nov. 30, 2017
Sep. 30, 2017
Sep. 30, 2016
Mar. 31, 2016
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2010
Dec. 31, 2015
Jan. 01, 2018
Dec. 31, 2017
Deferred Revenue Arrangement [Line Items]                          
Revenue recognized in period related to performance in prior periods               $ 28,000,000          
Potential future additional payments for development milestones               295,500,000          
Deferred revenue, current portion               19,531,000         $ 18,949,000
Deferred revenue, less current portion               12,808,000         19,021,000
Deferred revenue               $ 32,339,000         $ 37,970,000
AstraZeneca-Kirin [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments             40.00%            
Nektar's [Member] | NKTR-358 [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Received upfront and milestone payment         $ 150,000,000                
Percentage of sharing in Phase 2 development costs   25.00%                      
Regulatory milestones payment, description               A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.          
Deferred revenue               $ 17,600,000          
NKTR-214 [Member] | Nektar's [Member] | Subsequent Event [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Non-refundable upfront payment received in cash in future period     $ 1,000,000,000                    
NKTR-214 [Member] | Nektar's [Member] | Subsequent Event [Member] | Maximum [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones     1,430,000,000                    
Eligible additional cash payments receivable upon achievement of certain sales milestones     $ 350,000,000                    
NKTR-214 [Member] | Nektar's [Member] | BMS Collaboration Agreement [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Global commercialization profits and losses sharing percentage 65.00%                        
NKTR-214 [Member] | Nektar's [Member] | BMS Collaboration Agreement [Member] | Opdivo [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Percentage of sharing development costs 32.50%                        
NKTR-214 [Member] | Nektar's [Member] | BMS Collaboration Agreement [Member] | Opdivo and Yervoy [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Percentage of sharing development costs 22.00%                        
Baxalta Incorporated/Shire [Member] | Hemophilia                          
Deferred Revenue Arrangement [Line Items]                          
Received under right to sublicense agreement       $ 12,000,000                  
Baxalta Incorporated/Shire [Member] | Hemophilia | European Union [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Upfront and milestone payments received from license agreements               10,000,000          
Baxalta Incorporated/Shire [Member] | Hemophilia | ASC 606 [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Deferred revenue               1,000,000          
Baxalta Incorporated/Shire [Member] | Hemophilia | ASC 606 [Member] | European Union [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Development milestones received               10,000,000          
Bristol-Myers Squibb [Member] | Subsequent Event [Member] | Purchase Agreement [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Shares of common stock purchased     8,284,600                    
Sale of stock consideration expected to be received in future period     $ 850,000,000                    
Issued price per share     $ 102.60                    
Bristol-Myers Squibb [Member] | NKTR-214 [Member] | BMS Collaboration Agreement [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Global commercialization profits and losses sharing percentage 35.00%                        
Bristol-Myers Squibb [Member] | NKTR-214 [Member] | BMS Collaboration Agreement [Member] | Opdivo [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Percentage of sharing development costs 67.50%                        
Bristol-Myers Squibb [Member] | NKTR-214 [Member] | BMS Collaboration Agreement [Member] | Opdivo and Yervoy [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Percentage of sharing development costs 78.00%                        
Bristol-Myers Squibb [Member] | NKTR-214 [Member] | Clinical Trial Agreement [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Percentage of out-of-pocket costs to be reimbursed by partner           50.00%              
Eli Lilly and Company [Member] | NKTR-358 [Member] | ASC 606 [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Deferred revenue                       $ 19,900,000  
Eli Lilly and Company [Member] | NKTR-358 [Member] | License [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Received upfront and milestone payment         125,900,000                
Eli Lilly and Company [Member] | NKTR-358 [Member] | License [Member] | ASC 606 [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Revenue related to license activities         125,900,000                
Eli Lilly and Company [Member] | NKTR-358 [Member] | Phase 1 Clinical Development [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Received upfront and milestone payment         17,600,000                
Eli Lilly and Company [Member] | NKTR-358 [Member] | Phase 1 Clinical Development [Member] | ASC 606 [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Deferred revenue                       14,500,000  
Eli Lilly and Company [Member] | NKTR-358 [Member] | Drug Product Development [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Received upfront and milestone payment         $ 6,500,000                
Eli Lilly and Company [Member] | NKTR-358 [Member] | Drug Product Development [Member] | ASC 606 [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Deferred revenue                       $ 5,400,000  
Eli Lilly and Company [Member] | NKTR-358 [Member] | Maximum [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Potential future additional development and regulatory milestones   $ 250,000,000                      
Eli Lilly and Company [Member] | Nektar's [Member] | NKTR-358 [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Percentage of regulatory milestones payments will be reduced under certain conditions   50.00%                      
Percentage of regulatory milestones payments will be reduced if conditions occur   75.00%                      
Eli Lilly and Company [Member] | Nektar's [Member] | NKTR-358 [Member] | Maximum [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Percentage of funding phase 3 development costs on an indication by indication basis borne   25.00%                      
Eli Lilly and Company [Member] | Nektar's [Member] | NKTR-358 [Member] | Minimum [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Percentage of funding phase 3 development costs on an indication by indication basis borne   0.00%                      
Eli Lilly [Member] | NKTR-358 [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Percentage of sharing in Phase 2 development costs   75.00%                      
Amgen, Inc. [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Received upfront and milestone payment                   $ 50,000,000      
Amgen, Inc. [Member] | ASC 606 [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Deferred revenue               12,900,000          
AstraZeneca AB [Member] | MOVANTIK and MOVANTIK fixed-dose combination program [Member] | Upfront Payment Arrangement [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Received upfront and milestone payment                     $ 385,000,000    
AstraZeneca AB [Member] | MOVANTIK Fixed-dose Combination Program [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Potential contingent payments based on development events               75,000,000          
AstraZeneca AB [Member] | AstraZeneca-Kirin [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Received upfront and milestone payment                 $ 3,000,000        
Deferred revenue               0          
Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner             60.00%            
Other [Member]                          
Deferred Revenue Arrangement [Line Items]                          
Potential future additional payments for development milestones               45,500,000          
Deferred revenue               $ 800,000